Deal-Making

PPD beefing up biologics lab services in Ireland

Contract research organization (CRO) PPD will expand its biologics capabilities in Athlone, Ireland to include cell and gene therapy analytical testing. The 41,000 square foot Athlone facility will have a further 6,000 square feet of lab space added to it to feed the demand for biologics testing and to mirror expansions being made at PPD’s facility across the pond in Middleton, Wisconsin. “The Athlone facility enables us to partner closely with a wide variety of both European and global clients…

Separate together: Biotage buying purification firm PhyNexus

Swedish separations firm Biotage will add lab scale purification technology through its acquisition of PhyNexus. Financial details of the deal have not been divulged, but the California-based private firm PhyNexus has agreed to be acquired by Biotage this week. PhyNexus will bring an enabling automation platform based on Dual Flow Chromatography to Biotage’s bioprocess offering and increase the firm’s place in the downstream space. The technology enables miniaturized and parallel automated work-flows to address different laboratory purification processes. The Dual…

Axovant looks to CDMO Yposkesi for gene therapy scale up

Axovant Sciences has selected French CDMO Yposkesi as a strategic partner to help bring its neurologic and neuromuscular gene therapy candidates through the clinic. Contract development and manufacturing organization (CDMO) Yposkesi will utilize its adeno-associated virus (AAV) and lentiviral vector production capabilities to service the strategic agreement with Axovant. Swiss biotech Axovant has a pipeline of gene therapies targeting neurological and neuromuscular diseases. Financial details have not been divulged, but Alain Lamproye, CEO of Yposkesi, said it is a straight…

Small molecule M&A round-up: Roche buys Jecure, Arsanis and X4 merge

Bored of biologics? Tired of T-cells? Well BioProcess Insider takes a look at some of the big developments in the small molecule world. First up in this compendium is Swiss pharma giant Roche. The firm has acquired San Diego, California-based Jecure Therapeutics through its Genentech division. While Genentech is synonymous with biologics, Jecure’s business focuses on small-molecule therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) and liver fibrosis. Its lead candidate is an inhibitor of Nucleotide-binding oligomerization (NOD)-like Receptor Family…

GE plans purification platform production plant post Puridify purchase

GE Healthcare will open a biomanufacturing center in Stevenage, UK to support production of its fiber-based purification platform, which it acquired last year. In November 2017, bioprocessing equipment and consumables vendor GE Healthcare acquired Puridify – a spin-out from University College London, UK – for an undisclosed fee. The deal added early-stage tech platform FibroSelect, consisting of a nanofiber-based material to which ligands are attached to activate the platform for purification of biologics. A year on and the firm has…

EU gives conditional nod for Takeda Shire megamerger

The European Commission (EC) has approved Takeda’s $62 billion acquisition on the proviso the firm divests Shire’s inflammatory bowel disease (IBD) candidate. In May, Japanese firm Takeda struck a deal to acquire Ireland-headquartered rare diseases biopharmaceutical company Shire for $62 billion (€54 billion). Six months on, the merger is one step closer after receiving approval under the EU Merger Regulation, on the condition of divesting Shire’s IBD candidate SHP647. “We can today approve the merger between Shire and Takeda, but…

LG Chem teams with Cue Biopharma in $405m plus oncology deal

LG Chem Life Sciences will offer up its biomanufacturing experience and potentially add downstream capabilities for Cue Biopharma’s biologic candidates under terms of the strategic partnership. Korean chemical company LG Chem’s life science business and Massachusetts-based Cue Biopharma have entered into a multi-target strategic collaboration to develop multiple candidates using the Immuno-STAT biologic platform. Cue’s Immuno-STAT biologics are designed for targeted modulation of disease-associated T cells and lead candidate CUE-101 targets human papillomavirus (HPV)-associated cancers. Under terms of the deal,…

Lonza and Sartorius rejig cell culture media deal

Lonza says cell culture media is no longer simply a consumable but a critical part of the biomanufacturing process as it modifies its supply deal with Sartorius. In December 2012, contract development and manufacturing organization (CDMO) Lonza teamed up with bioprocessing equipment and consumables supplier Sartorius Stedim Biotech (SSB) for the supply and distribution of media and buffers used in the manufacture of protein-based therapeutics and vaccines. A shift in the arrangement now sees supply continue but under non-exclusive terms,…

BioLife eyes up M&A in ‘fragmented’ regenerative med supply space

The cell and gene therapy tool supplier space is ripe for consolidation says BioLife Solutions, which is evaluating several acquisition targets. For the third quarter 2018, regenerative medicine consumables and tools firm BioLife reported sales of its biopreservation media product of $5.3 million (€4.7 million), up 79% year-on-year. With the firm also turning a profit of $1.2 million for the period, CEO Michael Rice spoke about the scaling-up opportunities to take advantage of the continued demand from the cell and…

Biogen pays $670m to (nearly) match Samsung BioLogics in share of Bioepis

Biogen has upped its stake in Korean biologics and biosimilar developer Samsung BioLogics from 5.4% to 50%, minus one share. Samsung Bioepis was founded in 2012 and has since been one of a handful of drugmakers to see regulatory success with biosimilar products both in Europe and the US. A joint venture between Korean contract development and manufacturing organization (CDMO) Samsung BioLogics and biopharma firm Biogen, the former has until now been the dominant stakeholder, holding 94.6% of the firm.…